Myopia in Children: Low-Dose Atropine Eye Drop Medication in Early Stages

by | Jun 26, 2024 | Ophthalmology

Myopia in Children: Sterile Low-Dose Atropine Eye Drops

Myopia, commonly known as nearsightedness, is a significant concern within the United States, affecting a growing number of children. The condition often begins in childhood and can progress rapidly, leading to severe visual impairments and other ocular complications later in life. Addressing myopia as soon as possible, in childhood, may make all the difference.

The Promise of Low-Dose Atropine in Early Myopia Management

Emerging research, including influential studies like the LAMP2 trial, highlights the potential of low-dose atropine in managing myopia from its early stages. Specifically, formulations such as 0.05% and 0.01% atropine have shown promising results in slowing the progression of myopia by managing myopic shifts and axial elongation.

Related Articles

Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial

Low Dose Atropine in Preventing the Progression of Childhood Myopia: A Randomised Controlled Trial

Why Choose Compounded Low-Dose Atropine from HDRx?

Health Dimensions Clinical Pharmacy (HDRx), with PCAB-accredited sterile compounding capabilities, specializes in the preparation of low-dose atropine eye drops. Our collaboration with optometrists and ophthalmologists ensures that we provide tailored therapeutic options that align with each patient’s unique needs.

Professional Compounding Centers of America - PCCA member
  1. Precision and Safety: HDRx adheres to stringent compounding protocols (required to maintain PCAB accreditation) to ensure each batch of low-dose atropine is precisely formulated in state-of-the-art sterile compounding labs.
  2. Customized Patient Care: Recognizing the variability in myopia progression among children, HDRx offers customized atropine solutions, allowing for dosage adjustments based on individual factors.
  3. Proactive Myopia Control: By offering low-dose atropine, HDRx empowers eye care professionals to take a proactive approach in managing myopia, potentially mitigating the risk of future ocular pathologies.

Clinical Support and Future Directions in Myopia Control

The strategic use of low-dose atropine marks a significant advancement in myopia management, emphasizing early intervention. Reviews of recent clinical trials demonstrate the potential advantages of initiating atropine during the premyopic stage, thereby supporting its integration into standard myopia management protocols.

HDRx: Your Partner in Eye Health

HDRx is committed to enhancing health outcomes through specialized compounding services. Our collaboration with eye care professionals across the United States highlights our commitment to addressing significant health challenges like myopia. We ensure that all medications, including low-dose atropine eye drops, are compounded with the highest level of precision and care.

Parents considering low-dose atropine for their children’s myopia management, or healthcare providers looking to add this to their practice, will find that HDRx offers not only top-tier compounded medications but also detailed consultations to tailor health plans according to the latest research and clinical best practices.

Easily Prescribe Low Dose Atropine Sterile Eye Drops for Myopia

Low-dose atropine is becoming a cornerstone in proactive myopia management strategies, particularly for children at risk of developing severe myopia. Health Dimensions Clinical Pharmacy stands at the forefront of this field, providing expertise and personalized care to support vision health. Reach out to HDRx today to discuss how our compounded atropine solutions can contribute to comprehensive myopia management.


Sharma, I., Das, G. K., Rohatgi, J., Sahu, P. K., Chhabra, P., & Bhatia, R. (2023). Low Dose Atropine in Preventing the Progression of Childhood Myopia: A Randomised Controlled Trial. Current Eye Research, 48(4), 402-407. 

Yam, J. C., Zhang, X. J., Zhang, Y., Yip, B. H., Tang, F., Wong, E. S., … & Pang, C. P. (2023). Effect of low-concentration atropine eyedrops vs placebo on myopia incidence in children: the LAMP2 randomized clinical trial. Jama, 329(6), 472-481.

MPA logo - health dimensions clinical pharmacy is michigan pharmacists association member
PCAB Logo - HDRX is an Accredited Compounding Pharmacy
HDRX is an Alliance for Pharmacy Compounding member - logo
PCCA - Health Dimensions Clinical Pharmacy is a PCCA member
Health Dimensions is an APMS member
Pharmacy Compounding Accreditation Board - Logo
podiatry and compounding

How Podiatrists Work with Compounding Pharmacists

Regardless of the medications involved, the close partnership between a podiatrist and a compounding pharmacy provides ...

This is a Text Box


This is a CTA

Test box with CTA


This is a blurb

This is text on a blurb

Skip to content